SCHEMBL4679844

SCHEMBL4679844

O=C(Cc1ccoc1Cc1cccc(Cl)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.38
CYP3A4 P08684 1/20 0.37
MAPT P10636 2/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 1/20 0.35
THRB P10828 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPK1 P28482 1/20 0.34
MPO P05164 1/20 0.34
HPGD P15428 1/20 0.34
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
KDM4A O75164 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
MTNR1A P48039 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671545 0.92 CYP3A4 (0.39) HCAR2CYP3A4MAPTPDE3BPDE3A
SCHEMBL5899394 0.88 HCAR2 (0.38) HCAR2LMNATHRBMPOMAOA
SCHEMBL4675258 0.87 L3MBTL1 (0.31) MAPTLMNANPC1RAB9AKDM4C
SCHEMBL4677651 0.87 SLC6A2 (0.32) HCAR2
SCHEMBL4676413 0.86 KDM4C (0.39) MAPTALDH1A1SMN1; SMN2HPGDKDM4C
SCHEMBL4672982 0.85 TDP1 (0.38) ALDH1A1NPC1RAB9AMPOMAOB
SCHEMBL4672377 0.83 HCAR2 (0.39) HCAR2CYP3A4MAPTPDE3BPDE3A
SCHEMBL4676613 0.82 POLB (0.32) PDE3BPDE3AALDH1A1LMNASMN1; SMN2
SCHEMBL4673032 0.82 NPC1 (0.32) LMNANPC1RAB9A
SCHEMBL4679970 0.81 HCAR2 (0.39) HCAR2CYP3A4MAPTPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885CYP3A4 4/4885MAPT 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.